Turcotte Sandra, Chan Denise A, Sutphin Patrick D, Hay Michael P, Denny William A, Giaccia Amato J
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Cancer Cell. 2008 Jul 8;14(1):90-102. doi: 10.1016/j.ccr.2008.06.004.
Renal cell carcinomas (RCCs) are refractory to standard therapies. The von Hippel-Lindau (VHL) tumor suppressor gene is inactivated in 75% of RCCs. By screening for small molecules selectively targeting VHL-deficient RCC cells, we identified STF-62247. STF-62247 induces cytotoxicity and reduces tumor growth of VHL-deficient RCC cells compared to genetically matched cells with wild-type VHL. STF-62247-stimulated toxicity occurs in a HIF-independent manner through autophagy. Reduction of protein levels of essential autophagy pathway components reduces sensitivity of VHL-deficient cells to STF-62247. Using a yeast deletion pool, we show that loss of proteins involved in Golgi trafficking increases killing by STF-62247. Thus, we have found a small molecule that selectively induces cell death in VHL-deficient cells, representing a paradigm shift for targeted therapy.
肾细胞癌(RCCs)对标准疗法具有耐药性。在75%的肾细胞癌中,冯·希佩尔-林道(VHL)肿瘤抑制基因失活。通过筛选选择性靶向VHL缺陷型肾癌细胞的小分子,我们鉴定出了STF-62247。与具有野生型VHL的基因匹配细胞相比,STF-62247可诱导VHL缺陷型肾癌细胞的细胞毒性并减少肿瘤生长。STF-62247刺激产生的毒性通过自噬以不依赖缺氧诱导因子(HIF)的方式发生。必需自噬途径成分的蛋白质水平降低会降低VHL缺陷型细胞对STF-62247的敏感性。利用酵母缺失文库,我们发现参与高尔基体运输的蛋白质缺失会增加STF-62247的杀伤作用。因此,我们发现了一种小分子,它能选择性地诱导VHL缺陷型细胞死亡,这代表了靶向治疗的范式转变。